A landmark study from Northwestern Medicine's Canning Thoracic Institute, published in the Journal of the American Medical Association (JAMA), is challenging a long-standing medical doctrine: that stage IV lung cancer automatically disqualifies patients from receiving lung transplants.
The results are striking. Among 17 patients with medically refractory, lung-limited stage IV non-small cell lung cancer who received double lung transplants, 100% survived the first year. In contrast, only 41% of similar patients treated with conventional therapies — chemotherapy, radiation, and immunotherapy — survived one year.
A New Paradigm: Transplant Oncology
"This work changes what we can imagine for a highly selected group of patients who were previously considered beyond the reach of curative-intent intervention," said Dr. Ankit Bharat, chief of Thoracic Surgery at Northwestern Medicine and co-corresponding author of the study.
The research evaluated outcomes from the Double Lung Transplant Registry for Lung-Limited Malignancies (DREAM) — a pioneering program that is currently the only dedicated lung transplant program for advanced lung cancer patients in the United States.
Why This Approach Works
Most stage IV lung cancer patients have disease that has spread beyond the lungs. However, a distinct subset develops cancer that remains confined to both lungs even as it progresses to respiratory failure. For these patients, death comes not from systemic cancer, but from progressive failure of cancer-filled lungs.
The Northwestern team implemented a rigorous selection process, using advanced imaging and systematic invasive mediastinal evaluation to confirm disease was truly lung-limited. They also redesigned the surgical technique: patients are placed on heart-lung bypass, both cancer-ridden lungs are removed simultaneously with lymph nodes, the airways are washed to clear cancer cells, and new lungs are transplanted.
"These patients can have billions of cancer cells in the lungs, so we must be extremely meticulous to not let a single cell spill," Bharat said.
Organ Stewardship and the Path Forward
Remarkably, the 100% one-year survival among cancer transplant recipients exceeded the 88% survival among patients who received lung transplants for traditional reasons like cystic fibrosis or COPD — suggesting donated organs are not being wasted.
The authors caution that longer follow-up is needed, and that this approach is not appropriate for all stage IV patients. During follow-up, four of the 17 transplant recipients saw their cancer return, and two had died by the study's end in January 2026.
"This is not a claim that transplant restores normal life expectancy," Bharat emphasized. "It's evidence that a carefully selected group of patients facing otherwise poor near-term survival may have an opportunity for meaningful additional life."
